Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PI3K/mTOR Inhibitor
CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions. -
PI3K/mTOR Inhibitor
WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies. -
PI3K Inhibitor
PI3K-IN-30 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), demonstrating potent inhibition with IC50 values of 5.1 nM for PI3Kα, 136 nM for PI3Kβ, 30.7 nM for PI3Kγ, and 8.9 nM for PI3Kδ. This compound is suitable for studies investigating PI3K signaling pathways and their implications in cancer and other diseases. Its high specificity and potency make it a valuable tool for biochemical and cellular research focused on PI3K-related mechanisms. -
PI3Kδ Inhibitor
Roginolisib is a selective PI3Kδ inhibitor that exhibits potent activity with an IC50 of 145 nM. This compound demonstrates high selectivity against a broad panel of 278 additional kinases, making it a valuable tool for research in cell signaling pathways. Its application in studies targeting immune responses and cancer biology highlights the importance of PI3Kδ modulation in therapeutic development. -
PI3Kγ Inhibitor
PI3Kγ inhibitor AZ2 selectively targets phosphoinositide 3-kinase gamma (PI3Kγ) with a pIC50 value of 9.3, indicating potent inhibition. This compound is valuable for investigating the role of PI3Kγ in inflammatory and immune diseases, providing insights into potential therapeutic applications. Its specificity makes it a useful tool in biochemical and pharmacological studies related to immune regulation. -
PI3K Inhibitor
Duvelisib (R enantiomer) is a selective inhibitor of phosphoinositide 3-kinase (PI3K), targeting the delta and gamma isoforms. It exhibits antitumor activity by inhibiting cell proliferation and promoting apoptosis in various cancer models. This compound is primarily utilized in research focused on cancer treatment, immune response modulation, and signaling pathway analysis. -
PI3Kα Inhibitor
PF-06843195 is a highly selective inhibitor of the PI3Kα isoform, exhibiting an IC50 of 18 nM in Rat1 fibroblasts. With kinase inhibition constants (Kis) of less than 0.018 nM and 0.28 nM for PI3Kα and PI3Kδ respectively, this compound effectively suppresses the PI3K/mTOR signaling pathway. PF-06843195 demonstrates significant antitumor efficacy, making it a valuable tool for research applications targeting cancer biology and therapeutic development. -
PI3KC2α Inhibitor
MIPS-21335 is a selective inhibitor of PI3KC2α, exhibiting an IC50 value of 7 nM. Additionally, it demonstrates inhibition of PI3KC2β, p110α, p110β, and p110δ, with corresponding IC50 values of 43, 140, 386, and 742 nM. MIPS-21335 exhibits significant antithrombotic effects and is valuable for research into cardiovascular and metabolic diseases, including thrombosis and hyperlipidemia. -
PI3Kγδ Inhibitor
AZD8154 is a selective dual inhibitor of the PI3Kγ and PI3Kδ isoforms. By effectively suppressing the activation of these signaling pathways, AZD8154 demonstrates potential in modulating inflammatory responses. This reagent is suitable for research in inflammation and immunology, particularly in studies related to asthma and other related conditions. -
PI3K Inhibitor
PIT-1 is a selective inhibitor of phosphatidylinositol 3,4,5-trisphosphate (PIP3) that targets the PI3K/Akt signaling pathway. By inhibiting PIP3, PIT-1 effectively disrupts cancer cell survival and promotes apoptosis. This compound demonstrates significant antitumor activity in vivo, making it suitable for investigations into cancer therapeutics and signaling pathways involved in oncogenesis. -
PI3Kδ Inhibitor
Leniolisib phosphate is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway. This compound exhibits significant biological activity in modulating immune responses, making it a valuable tool for research in immunodeficiency disorders. Its mechanism of action underscores its potential in therapeutic applications targeting underlying immunological defects. -
PI3K Inhibitor
PI3K-IN-31 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), displaying IC50 values of 3.7 nM for PI3Kα, 74 nM for PI3Kβ, 14.6 nM for PI3Kγ, and 9.9 nM for PI3Kδ. Its selective inhibition of these kinases correlates with significant anticancer activity, making it a valuable tool in cancer research. Applications for PI3K-IN-31 include studying the PI3K signaling pathway and evaluating its role in tumorigenesis and therapeutic resistance. -
PI3Kα Inhibitor
(S)-PI3Kα-IN-4 is a highly selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform, demonstrating an IC50 value of 2.3 nM. This compound exhibits significant selectivity, with 38.3-fold preference for PI3Kα over PI3Kβ, and more than 4-fold selectivity compared to PI3Kδ and PI3Kγ. (S)-PI3Kα-IN-4 is suitable for research applications focusing on cancer biology, particularly in studies aimed at understanding the role of PI3Kα in tumorigenesis and therapeutic resistance. -
PI3K Inhibitor
Vulolisib is a potent, orally active inhibitor of phosphatidylinositol 3-kinase (PI3K), demonstrating IC50 values of 0.2 nM for PI3Kα, 168 nM for PI3Kβ, 90 nM for PI3Kγ, and 49 nM for PI3Kδ. This compound exhibits significant antiproliferative and antineoplastic properties, making it a valuable tool for cancer research. Its selective inhibition of PI3K isoforms facilitates investigations into the role of PI3K signaling in various malignancies. -
PI3Kδ/γ Inhibitor
PI3Kδ/γ-IN-1 is a selective inhibitor targeting phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ), demonstrating high potency in inhibiting their activity. This compound plays a pivotal role in the study of hematological malignancies, facilitating research into the underlying molecular mechanisms and potential therapeutic approaches for conditions such as leukemia and lymphoma. Its specificity for PI3Kδ and PI3Kγ makes it an invaluable tool for investigating the contributions of these isoforms in cancer biology. -
PI3Kγ Inhibitor
NVS-PI3-4 is a selective inhibitor of PI3Kγ, playing a crucial role in modulating the PI3K signaling pathway. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating the mechanisms underlying allergies, inflammatory disorders, and various cancer types. Researchers can utilize NVS-PI3-4 to explore therapeutic strategies aimed at targeting PI3Kγ-related pathways in relevant disease models. -
PI3Kα Inhibitor
Benzoin is a potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) signaling pathway, known for its potential anticancer effects. This compound has been shown to effectively impede the growth of the colon cancer cell line HCT-116, making it a valuable tool for cancer research. Its application in studying PI3Kα-mediated processes provides insights into therapeutic strategies for colon malignancies. -
PI3Kγ Inhibitor
AS-041164 is a selective inhibitor of the PI3Kγ isoform, demonstrating a potent inhibitory effect with an IC50 of 70 nM. This compound exhibits significantly reduced activity against other isoforms, including PI3Kα, PI3Kβ, and PI3Kδ, with IC50 values of 240 nM, 1.45 μM, and 1.70 μM, respectively. AS-041164 is recognized for its anti-inflammatory properties and is applicable in research focused on inflammation-related pathways and diseases. -
PI3Kβ Inhibitor
MIPS-9922 is a potent and selective inhibitor of PI3Kβ, exhibiting an IC50 of 63 nM. This compound demonstrates over 30-fold higher potency for PI3Kβ compared to PI3Kδ. MIPS-9922 effectively disrupts PI3K-mediated activation of platelet glycoprotein αIIbβ3 and platelet adhesion in vitro, making it a valuable tool for studying anti-platelet and anti-thrombotic activities in research applications. -
PI3Kδ Inhibitor
Parsaclisib hydrochloride is a selective inhibitor of PI3Kδ, exhibiting an IC50 of 1 nM in the presence of 1 mM ATP. With approximately 20,000-fold selectivity over other PI3K class I isoforms, this orally active compound is valuable for investigating the biochemical pathways involved in B-cell malignancies. It is particularly useful in research focused on relapsed or refractory forms of these cancers. -
PI3Kα Inhibitor
PI3Kα-IN-4 is a selective, potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 value of 1.8 nM. This orally active compound exhibits significant antitumor activity, making it a valuable tool in cancer research. It is primarily used for investigating the role of PI3Kα in oncogenesis and therapeutic resistance. -
PI3K Inhibitor
PI3K-IN-36 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a critical enzyme involved in cell signaling pathways. This compound exhibits significant biological activity and is primarily utilized in research focused on follicular lymphoma (FL). Its effectiveness as a PI3K inhibitor makes it a valuable tool for investigating the underlying mechanisms of cancer and testing potential therapeutic strategies. -
PI3Kδ Inhibitor
Roginolisib hemifumarate is a selective inhibitor of the PI3Kδ isoform with an IC50 of 145 nM. This compound demonstrates significant selectivity across a broad panel of 278 additional kinases, making it a valuable tool for the study of signaling pathways involving PI3Kδ. Its potency and specificity facilitate research applications in cancer biology and immune modulation. -
PI3Kβ/δ Inhibitor
PI3K-IN-2 is a potent and orally bioavailable inhibitor of PI3Kβ and PI3Kδ, exhibiting IC50 values of 7.1 nM and 8.6 nM, respectively. This compound demonstrates excellent selectivity over other isoforms, such as PI3Kσ and PI3Kγ, with IC50 values of 13 nM and 190 nM. Due to its specificity and potency, PI3K-IN-2 is suitable for research applications focusing on cancer, inflammation, and other diseases associated with dysregulated PI3K signaling pathways. -
PI3K Inhibitor
PI3K-IN-18 dihydrochloride is a selective inhibitor of the PI3K p110α isoform, derived from a 4-morpholino-2-phenylquinazoline structure. This compound demonstrates significant biological activity in attenuating the PI3K signaling pathway, which plays a crucial role in cell growth, proliferation, and survival. Research applications include cancer biology, where modulation of PI3K activity can provide insights into tumor progression and therapeutic responses. -
PI4K/PI3K Inhibitor
(S)-GSK-F1 is a potent inhibitor of type III phosphatidylinositol 4-kinase α (PI4KIIIα). It demonstrates inhibitory activity against various kinases, including PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ, and PI3Kδ, with pIC50 values of 8.3, 6.0, 5.6, 5.6, 5.1, and 5.6, respectively. (S)-GSK-F1 has been shown to effectively inhibit hepatitis C virus (HCV) replication, making it a valuable tool for research in viral infections and signaling pathways. Its moderate pharmacokinetic profiles in rat models support its potential for in vivo studies. -
PI3K Inhibitor
(S)-PI3K-IN-2 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) isoforms β and δ, exhibiting IC50 values of 0.198 μM and 0.282 μM, respectively. This compound effectively inhibits phosphorylation of AKT at serine 473 in MDA-MB-468 cancer cells, demonstrating an IC50 of 27 nM. (S)-PI3K-IN-2 is a valuable tool for investigating PI3K signaling pathways and their implications in cancer research. -
PI3Kδ Inhibitor
PI3Kδ-IN-15 is a highly selective inhibitor of the PI3Kδ isoform, demonstrating an IC50 of 0.5 nM specifically for the p110δ subunit. This compound exhibits over 30-fold greater potency against PI3Kδ compared to other isoforms including PI3Kγ, PI3Kβ, and PI3Kα. PI3Kδ-IN-15 is valuable for research applications targeting immune cell signaling and cancer biology, aiding in the exploration of therapeutic strategies for diseases associated with aberrant PI3Kδ activity. -
PI3K Inhibitor
PI3Kδ-IN-9 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.8 nM. It effectively modulates signaling pathways related to immune responses and inflammation. This compound is utilized in research applications focused on cancer, autoimmune diseases, and other conditions where PI3Kδ plays a critical role in cellular processes. -
PI3K Inhibitor
Vps34-IN-3 is a selective inhibitor of the VPS34 kinase, a key component of the phosphoinositide 3-kinase (PI3K) signaling pathway. This compound exhibits potent activity, making it suitable for research applications aimed at understanding lipid metabolism, autophagy, and cellular signaling processes. Its oral bioavailability enhances its utility in preclinical studies. -
PI3K Inhibitor
Nemiralisib hydrochloride is a potent and highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting a pKi of 9.9. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research related to cancer and autoimmune diseases. Its selective inhibition of PI3Kδ makes it a valuable tool for investigating the roles of this pathway in various cellular processes and therapeutic interventions. -
BTK/PI3Kδ Inhibitor
MDVN1003 is a dual inhibitor of Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ). This compound effectively inhibits B cell activation and blocks the phosphorylation of protein kinase B (AKT) as well as extracellular signal-regulated kinases 1 and 2 (ERK 1/2). MDVN1003 is primarily utilized in research related to non-Hodgkin’s lymphoma (NHL), offering insights into the underlying mechanisms of lymphocyte-driven malignancies. -
PI3Kδ Inhibitor
PI3Kδ-IN-8 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.3 nM. It demonstrates a pronounced selectivity for PI3Kδ compared to PI3Kα, PI3Kβ, and PI3Kγ, exhibiting IC50 values of 377.2 nM, 241.6 nM, and 17.9 nM, respectively. This compound has shown significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and cellular signaling pathways involving PI3Kδ. -
PI3K Inhibitor
GSK251 is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) isoform, exhibiting a novel binding mechanism. It demonstrates significant biological activity by effectively impeding PI3Kδ signaling pathways, which are crucial in various immune responses and hematological malignancies. GSK251 is utilized in research applications focused on understanding the role of PI3Kδ in cancer therapy and immune modulation. -
PI3Kδ Inhibitor
CHF-6523 is a selective inhibitor of PI3Kδ, which plays a crucial role in cellular signaling pathways. This compound exhibits potent biological activity in modulating immune responses and has been employed in research focused on chronic obstructive pulmonary disease (COPD). Its ability to inhibit PI3Kδ makes it a valuable tool for investigating therapeutic strategies targeting immune and inflammatory processes associated with COPD. -
PI3Kδ Inhibitor
PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ, demonstrating an IC50 of 8.9 nM. This compound effectively modulates PI3K signaling pathways, making it a valuable tool in research focused on cancer and immune responses. It is applicable in studies evaluating the role of PI3Kδ in various diseases, including hematological malignancies and inflammatory disorders. -
PI3Kγ Inhibitor
PI3Kγ Inhibitor 4 is a selective, orally bioavailable inhibitor targeting the phosphoinositide 3-kinase gamma (PI3Kγ) enzyme, demonstrating an IC50 of 40 nM. It exhibits notable selectivity ratios of approximately 7-fold, 43-fold, and 18-fold against the α, β, and δ isoforms, respectively. This compound is valuable for studying airway inflammation and may contribute to understanding associated pathological conditions. -
PI3Kα Inhibitor
PI3K-IN-63 is a potent inhibitor of PI3Kα, exhibiting a Ki of 0.35 nM against human targets. This compound effectively inhibits the phosphorylation of AKT at the S473 site in cellular assays, demonstrating its capacity to interfere with critical signaling pathways. PI3K-IN-63 has shown efficacy in reducing the viability of non-small cell lung cancer cell lines harboring PIK3CA mutations, making it a valuable tool for research related to this type of cancer. -
PI3K Inhibitor
Amdizalisib is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, which plays a crucial role in various cellular functions, including metabolism, growth, and survival. This compound demonstrates significant anti-proliferative effects in cancer cells and modulates immune responses, making it a valuable reagent for research applications focused on inflammatory diseases, autoimmune disorders, and oncology. Amdizalisib serves as an important tool for advancing the understanding of PI3K-related mechanisms in both disease states and therapeutic development. -
PI3Kδ Inhibitor
AM-8508 is a potent PI3Kδ inhibitor, demonstrating an IC50 of 0.016 μM. It selectively targets PI3Kδ, effectively blocking AKT phosphorylation associated with B cell receptor signaling. Research has shown that AM-8508 suppresses the production of antigen-specific IgG and IgM in immunized rats, highlighting its potential applications in the study of inflammatory diseases. This compound serves as a valuable tool for investigating the role of PI3Kδ in immune responses. -
PI3Kδ Inhibitor
AM-1430 is a highly selective and orally active inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) enzyme, with an IC50 value of 4.6 nM. This compound demonstrates significantly higher IC50 values for PI3Kα, PI3Kβ, and PI3Kγ, at 14.18 μM, 2.2 μM, and 3.22 μM, respectively. AM-1430 effectively inhibits B cell proliferation and shows strong in vivo activity, particularly in models of pAKT inhibition and hemoglobin (KLH) immune response. This reagent is suitable for research focused on inflammation and autoimmune diseases. -
PI3K Inhibitor
PI3Kα-IN-12 is a highly selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 of 1.2 nM. It demonstrates significant antiproliferative activity against HCT-116 and U87-MG cell lines, with IC50 values of 0.83 μM and 1.25 μM, respectively. In vivo, PI3Kα-IN-12 induces tumor regression in a U87-MG xenograft model at a dosage of 40 mg/kg administered intraperitoneally, making it a valuable tool for research on cancer therapy targeting the PI3K signaling pathway. -
PI3Kα Inhibitor
PI3Kα-IN-19 is a selective inhibitor of PI3Kα, targeting the p110α catalytic subunit. This compound demonstrates significant biological activity in inhibiting the PI3Kα pathway, which is frequently dysregulated in various cancers. PI3Kα-IN-19 is valuable for researching cancer biology and evaluating therapeutic strategies that involve modulation of the PI3Kα signaling pathway. -
FAP-PI3K Inhibitor
FAP-PI3KI1 is a fibroblast-activated protein (FAP) inhibitor that selectively targets the phosphoinositide 3-kinase (PI3K) pathway in FAP-expressing human cells. This compound effectively inhibits collagen synthesis and reduces collagen deposition, making it a valuable tool for research in idiopathic pulmonary fibrosis (IPF) and related fibrotic conditions. Its targeted action facilitates investigating the role of the PI3K signaling pathway in fibrosis and offers potential insights into therapeutic strategies for IPF. -
PI3K Inhibitor
PI3K-IN-27 is a targeted inhibitor of phosphoinositide 3-kinase (PI3K), a critical component in cellular signaling pathways that govern processes such as cell growth, differentiation, migration, and apoptosis. This compound exhibits potent inhibitory activity against PI3K, making it valuable for investigating hyper-proliferative diseases, including cancer and inflammation, as well as immune and autoimmune disorders. Its role in modulating PI3K activity underscores its potential utility in preclinical research settings. -
PI3K Inhibitor
PI3K-IN-28 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), showcasing significant potency in inhibiting its activity. With half-maximal inhibitory concentration (IC50) values of 5.8, 2.3, and 7.9 µM, PI3K-IN-28 demonstrates reduced toxicity in MCF-10a cell lines and a selectivity index (SI) of 39, highlighting its potential for anticancer applications. This compound serves as a promising lead for further development of targeted therapeutics in cancer research. -
PI3Kδ Inhibitor
Dezapelisib is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) that demonstrates significant antitumor activity. This compound is primarily utilized in research focused on relapsed or refractory B-cell lymphomas, making it a valuable tool for understanding the therapeutic potential of targeted PI3Kδ inhibition in hematological malignancies. Its mechanism of action contributes to the modulation of cell proliferation and survival pathways, offering insights into cancer treatment strategies. -
PI3K Inhibitor
PI3K-IN-38 is an orally active inhibitor of phosphoinositide 3-kinase (PI3K), with an IC50 of 0.541 µM for PI3K-α. This compound demonstrates significant anticancer and anti-inflammatory properties, effectively inhibiting tumor growth in vivo. Its selective modulation of the PI3K pathway makes it a valuable tool for research into cancer therapies and inflammatory diseases. -
Pan-class I PI3K Inhibitor
NVP-CLR457 is a potent pan-class I PI3K inhibitor that exhibits oral bioavailability and a favorable pharmacokinetic/pharmacodynamic relationship. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. NVP-CLR457 is suitable for studies focused on the roles of PI3K signaling in various cancer types and therapeutic resistance mechanisms.
